Affiliates of ACON Latin America Opportunities Fund IV, L.P., in partnership with Humus Capital Partners a private equity firm based in Argentina, have acquired a majority equity interest in Biosidus S.A. and Biosidus Farma S.A. Biosidus S.A., a biotechnology company, develops, manufactures, and supplies biosimilars and Biosidus Farma S.A. manufactures and distributes biosimilar pharmaceuticals with exports worldwide to more than 25 countries across four continents. ACON and HCP will continue Biosidus’ international expansion strategy, building on its track record of more than 150 million doses of biosimilar pharmaceuticals produced over the last two decades. Santiago García Belmonte, Biosidus’ CEO and current shareholder, said, “I believe that this investment confirms the value our team has built in Biosidus as one of the premier biosimilar pharmaceutical companies in Latin America and the outstanding opportunities presented by biosimilars around the world. We have been searching for the right partners to take our company to the next level and help us capture those opportunities, and I believe that we have found them in ACON and HCP.”